- Specialization
- Biotechnology
- Business
- Scientific Research
- Market
- Healthcare
- Ecosystem
- Not applicable
- Customers
Enterprisesand 1 more customers valuesLess
- Small Businesses
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology
- Market
- Healthcare
- Customers
- Enterprises, Small Businesses
- Delivery models
- Physical Goods
- Revenue models
- Product Sales
- Listing status
- Not classified
- Latest equity round
- Series A
- Reported funding amount
- Not classified
About
TYBR Health develops the B3 GEL System, an FDA-cleared, flowable extracellular-matrix hydrogel designed to protect tendons, ligaments, muscles, and surrounding soft tissue during post-surgical healing. It sells to orthopedic surgeons and practices, differentiating through a bioabsorbable gel that adheres where applied, conforms to anatomy, and creates a protective barrier without adding procedural complexity.
Market
TYBR Health competes in regenerative medicine and orthopedic medical devices, specifically the market for tendon-repair protection and postoperative anti-adhesion barriers. Its positioning is an FDA-cleared, collagen-based, bioresorbable gel that protects healing tissue and preserves tendon mobility. It differentiates from sheet- and mesh-based barriers through a flowable, conforming gel, thermally responsive placement, visual coverage confirmation, and a proprietary delivery system designed to integrate with surgical workflows.
TYBR Health primarily targets orthopedic, hand, and other musculoskeletal surgeons, along with specialty surgical practices, hospitals, and ambulatory surgery centers performing tendon, ligament, and soft-tissue repairs. The principal buyer and user is the surgeon seeking to reduce postoperative adhesions and preserve patient mobility during healing.
At a Glance
Problem
TYBR Health addresses the “mobility gap” that can remain after technically successful tendon and soft-tissue surgery. Post-operative adhesions, scarring, and tissue tethering can prevent a repaired tendon from gliding normally, leaving patients with persistent functional limitations despite structural healing. The company says up to 40% of tendon-repair patients may face lifelong mobility limitations; its identified U.S. opportunity includes roughly 110,000 hand, wrist, foot, and ankle tendon procedures annually, with 7–17% of flexor tendon repairs still requiring re-operation. The economic burden extends beyond revision surgery to prolonged therapy, workplace accommodations, and quality-of-life costs. The clearest use case is flexor tendon repair or reconstruction—especially in the hand and wrist—where early, unrestricted tendon motion is essential to regain function.
Product / Service
The B3 GEL™ System is an FDA-cleared, flowable collagen-based extracellular-matrix hydrogel used as an intraoperative surgical adjunct. A proprietary mixer-applicator delivers the blue, visually trackable gel directly over the repair, where it conforms to complex anatomy, sets within approximately two to three minutes, and acts as a temporary biomechanical spacer during the critical healing period. The gel is designed to maintain separation between healing tissues, reduce restrictive adhesion formation, and then naturally resorb within roughly 30 days. Unlike sheet- or fabric-based barriers, it is intended to cover irregular tissue surfaces without leaving gaps or dislodging, while integrating into existing open or minimally invasive surgical workflows.
Market
TYBR competes in orthopedic medical devices, regenerative medicine, and anti-adhesion or tissue-protection products used after tendon, ligament, muscle, and other soft-tissue procedures. The closest identified alternatives are Alafair Biosciences’ VersaWrap and Miromatrix’s Biological Mesh, which the FDA lists as predicate devices for TYBR’s collagen gel; more broadly, TYBR positions B3 GEL against conventional membrane, fabric, and film barriers. Its differentiation is a flowable, conforming ECM gel rather than a preformed sheet, with the goal of preserving tendon glide and reducing downstream rehabilitation or revision needs.
The company received FDA 510(k) clearance in June 2025, announced its first U.S. clinical use in January 2026, and reported that the initial surgeon subsequently used B3 GEL in two additional flexor tendon cases. By July 2026, TYBR said the system had been used in hand, wrist, shoulder, foot and ankle, and sports-medicine procedures, and described early commercial traction. It also announced a $30 million Series A to expand commercial access, broaden indications, and fund clinical studies. The available evidence supports an early commercial-stage company rather than a purely preclinical venture, although it does not disclose revenue or customer-count figures.
Founders & Leadership
Funding History
Not publicly disclosed
Johnson & Johnson Innovation - JLABS
Vensana Capital, Mutual Capital Partners
Recent News
TYBR Health was reported to have filed a notice of exempt offering with the SEC to raise up to $30 million in new funding. The filing concerns the Houston-based company’s orthopedic biomaterial therapies and B3 GEL system.
TYBR Health reported the first U.S. clinical use of its collagen-based B3 GEL System, a tissue protector intended to support post-surgical healing in orthopedic soft-tissue procedures.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
TYBR Health makes money by commercializing the B3 GEL System as a medical-device product for orthopedic surgeons and practices, with adoption across hand, wrist, shoulder, foot-and-ankle, and sports-medicine procedures. Public evidence does not specify unit pricing, reimbursement, licensing terms, or other revenue streams.